Morgan Stanley raised the firm’s price target on Hologic (HOLX) to $76 from $69 and keeps an Equal Weight rating on the shares after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share. The firm views the proposed acquisition price as “a fair valuation” and doesn’t expect any barriers to the transaction closing in the first half of 2026, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic Updates Restricted Stock Unit Award Agreement
- Cautious Hold Rating for Hologic Amid Strong Q4 Results and Future Uncertainties
- Hologic’s Mixed Performance and Acquisition Uncertainty Lead to Hold Rating
- Hologic reports Q4 adjusted EPS $1.13, consensus $1.10
- Notable companies reporting after market close